Firalis is partnering with Institut de recherche en hématologie et transplantation (IRHT) on the DiaBioLiq Research Project to improve brain cancer diagnosis.

Towards better patient care and management

"DiaBioLiq" - Diagnostic via Liquid Biopsy, is an innovative project seeking to simplify brain cancer detection without invasive biopsies, minimizing patient risks. Leveraging cerebrospinal fluid samples obtained through lumbar puncture, DiaBioLiq promises a safer and more accessible diagnostic approach.

Firalis will contribute to the project with its expertise in developing high-quality diagnostic kits.

More information

Details

17 Rue du Fort, 68330 Huningue, France

AMONETA - FIRALIS

Associated Trend items

Amoneta Diagnostics at 2024 Clinical Trials on Alzheimer's Disease (CTAD)

Introducing our Research on Advancing Alzheimer’s Disease Stratification

We are excited to announce that our team will not only be attending but also presenting at the 2024 Clinical Trials on Alzheimer’s Disease (CTAD) conference. During the second poster session on October 31st, we will present our poster number 00492, which introduces an innovative approach to Alzheimer’s patient stratification by combining “static” genetic data from our A...

More information

Amoneta Diagnostics obtains CE-marking certification under the IVDR for APO-Easy® Genotyping Kit

Amoneta Diagnostics SAS, a biotech company specialized in developing innovative biomarkers for neurodegenerative disease, proudly announces that its APO-Easy® Genotyping Kit has achieved CE-marking under the EU In Vitro Diagnostic Regulation 2017/746

Huningue, France – 20/08/2024 – Amoneta Diagnostics SAS, a biotech company specialized in developing innovative biomarkers for neurodegenerative disease, proudly announces that its APO-Easy® Genotyping Kit has achieved CE-marking under the EU In Vitro Diagnostic Regulation 2017/746 (IVDR). The IVDR certification was issued by the Notified Body BSI after successful stages...

More information

Amoneta Diagnostics attends the AD/PD™ 2024 International Conference

We are innovators in the pursuit of scientific progress and therapeutic advancements for neurodegenerative disorders.

Amoneta Diagnostics announces its participation in the AD/PD™ 2024 International Conference on Alzheimer’s and Parkinson’s Diseases in Lisbon. As innovators in the pursuit of scientific progress and therapeutic advancements for neurodegenerative disorders, we have had opportunity to engage with fellow experts and present our latest innovation: the APO-Easy® Genotyping Ki...

More information

Products associated

solution reagent kit

NeuroDeGene®

neurodegenerative disease test kit

NeuroLINCs

Compare

Remove all

Compare up to 10 products